Literature DB >> 8512683

A scientific rationale for protective therapy in Parkinson's disease.

C W Olanow1.   

Abstract

The desire to introduce neuroprotective therapy for Parkinson's disease has begun to focus attention on pathogenetic mechanisms responsible for cell death. Considerable theory and some evidence have now accumulated to suggest that factors related to oxidative stress, mitochondrial bioenergetic defects, excitatory neurotoxicity, calcium cytotoxicity, and trophic factor deficiencies acting either singularly or in combination may contribute to the development of cell death in Parkinson's disease. A better understanding of the specific pathogenetic mechanism involved in cell degeneration might provide a scientific basis for testing a putative neuroprotective therapy. This chapter reviews the theory and evidence in support of these different mechanisms and possible strategies that might provide neuroprotection and interfere with the natural progression of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8512683     DOI: 10.1007/BF01245230

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  117 in total

1.  Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence.

Authors:  S Ikebe; M Tanaka; K Ohno; W Sato; K Hattori; T Kondo; Y Mizuno; T Ozawa
Journal:  Biochem Biophys Res Commun       Date:  1990-08-16       Impact factor: 3.575

Review 2.  Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?

Authors:  C W Olanow; D Calne
Journal:  Neurology       Date:  1992-04       Impact factor: 9.910

Review 3.  Excitatory amino acid transmitters.

Authors:  J C Watkins; R H Evans
Journal:  Annu Rev Pharmacol Toxicol       Date:  1981       Impact factor: 13.820

4.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra.

Authors:  C Hyman; M Hofer; Y A Barde; M Juhasz; G D Yancopoulos; S P Squinto; R M Lindsay
Journal:  Nature       Date:  1991-03-21       Impact factor: 49.962

5.  Chronic quinolinic acid lesions in rats closely resemble Huntington's disease.

Authors:  M F Beal; R J Ferrante; K J Swartz; N W Kowall
Journal:  J Neurosci       Date:  1991-06       Impact factor: 6.167

6.  Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects.

Authors:  W Koek; F C Colpaert
Journal:  J Pharmacol Exp Ther       Date:  1990-01       Impact factor: 4.030

7.  GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.

Authors:  M Hadjiconstantinou; A P Mariani; N H Neff
Journal:  Brain Res       Date:  1989-04-10       Impact factor: 3.252

Review 8.  The release and uptake of excitatory amino acids.

Authors:  D Nicholls; D Attwell
Journal:  Trends Pharmacol Sci       Date:  1990-11       Impact factor: 14.819

9.  Cerebral and ocular toxicity induced by desferrioxamine.

Authors:  D R Blake; P Winyard; J Lunec; A Williams; P A Good; S J Crewes; J M Gutteridge; D Rowley; B Halliwell; A Cornish
Journal:  Q J Med       Date:  1985-07

10.  Lathyrism: evidence for role of the neuroexcitatory aminoacid BOAA.

Authors:  P S Spencer; D N Roy; A Ludolph; J Hugon; M P Dwivedi; H H Schaumburg
Journal:  Lancet       Date:  1986-11-08       Impact factor: 79.321

View more
  2 in total

1.  VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress.

Authors:  R A Steingart; B Solomon; D E Brenneman; M Fridkin; I Gozes
Journal:  J Mol Neurosci       Date:  2000-12       Impact factor: 3.444

Review 2.  Perspectives on MAO-B in aging and neurological disease: where do we go from here?

Authors:  M Jyothi Kumar; Julie K Andersen
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.